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An aptamer-capped mesoporous material for the selective 
and sensitive detection of α-thrombin in human plasma and 
serum has been prepared and characterised. 
The design of stimuli-responsive nanoscopic gated systems 
involving biomolecules has recently drawn much attention. In 
particular, some biomolecules, especially enzymes,1 have been 
used as stimuli to uncap gated-scaffolds, whereas others, such as 
saccharides,2 antibodies,3 peptides4 or DNA,5 have acted as 
capping agents. Capped materials have been used mainly in drug 
delivery applications. However, there are by far fewer examples 
of their use in sensing.3 In the latter approach, the carrier system 
is loaded with a dye and the capped mechanism is designed so 
that only a target analyte is able to trigger the delivery of the 
cargo. Among the different biomolecules that could act as caps, 
aptamers are especially appealing to design gated nanodevices for 
sensing and targeting applications.6  
 Furthermore, α-thrombin is a coagulation protein that has 
many effects on the coagulation cascade and its determination 
can be used to understand thrombosis and homeostasis processes. 
This protein, also known as coagulation factor II, is a serine 
protease that converts soluble fibrinogen (factor I) into insoluble 
strands of fibrin (factor Ia).7,8 The concentration of α-thrombin in 
blood varies considerably and can be virtually absent in healthy 
subjects. However in the coagulation process, the concentration 
of thrombin in blood ranges from nM to low μM levels.9 
Moreover, it is important to detect thrombin in blood serum for 
clinical and diagnostic applications.10 
 Recently, various aptasensors based on electrochemistry,11 
colorimetry,12 fluorescence,13 electrochemiluminescence,14 and 
other techniques15 for thrombin detection have been developed. 
For instance, electrochemical aptasensors for thrombin detection 
based on nanoparticle labeling have also been described. For 
labeling purposes, gold nanoparticles,16  quantum dots17 or carbon 
nanotubes18 have been widely used. One of the most commonly 
used aptamers in the development of thrombin aptasensors is the 
15-mer DNA aptamer d(5’-GGT TGG TGT GGT TGG-3’), also 
known as thrombin-binding aptamer (TBA),19 which is able to 
bind selectively onto exosite I thrombin (fibrinogen-binding sites) 
with a high specificity versus other substances.20   
  Despite the above examples, as far as we know, the use of 
TBA gated-hybrid mesoporous materials to recognize thrombin 
has not yet been reported. By taking these facts into account, this 
work presents a new hybrid gated material for the fluorometric 
detection of α-thrombin. Based on our experience in the field of 
bio-gated hybrid materials for sensing applications21 we report 
herein the preparation of an aptamer-gated silica mesoporous 
supports for the selective and sensitive fluorogenic signaling of α-
thrombin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Schematic representation of the gated material S1 
functionalised with 3-aminopropyltriethoxysilane and capped with a TBA 
aptamer in the quadruplex state (S1-TBA). The delivery of the entrapped 
guest (rhodamine B) is observed in the presence of α-thrombin.  
 
 Scheme 1 shows the proposed paradigm for thrombin detection 
using capped mesoporous materials. MCM-41 mesoporous 
nanoparticles (diameter of ca. 100 nm) were selected as inorganic 
scaffolds and pores were loaded with a fluorophore (rhodamine 
B). Then the external surface of the loaded support was 
functionalised with 3-aminopropyltriethoxysilane (APTS) (solid 
S1). Aminopropyl moieties are partially charged at a neutral pH 
and should display electrostatic interactions with the negatively 
charged TBA aptamer. Addition of TBA yielded the final capped 
hybrid material S1-TBA. Specifically for the preparation of the 
gated material S1-TBA, 1.5 mg of S1 were suspended in 1.5 mL 
of simulated human blood plasma (pH 7.25).22 Then, 60 µl of 
TBA (28 µM) were added to 150 µl of the S1 suspension. The 
final S1-TBA solid was isolated by centrifugation and washed 
with 300 µl of simulated human blood plasma to eliminate the 
residual dye and the free TBA. 
 S1 was characterised by standard procedures. The X-ray 
pattern of S1 shows the mesoporous characteristic (100) peak 
diffraction, indicating that the loading process with the dye and 
the further functionalisation with APTS did not damage the 
mesoporous scaffolding (see Figure S2). The presence of the 
mesoporous structure in the final functionalised solids is also 
clearly observed from the TEM analysis (see Figure S2). The N2 
adsorption-desorption isotherms of the calcined MCM-41 
nanoparticles (Figure S3) shows an adsorption step with an 
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intermediate P/P0 value (0.1–0.3). From this curve, a pore volume 
of 0.84 cm3 g-1 was calculated by the BJH model on the 
adsorption branch of the isotherm. The application of the BET 
model resulted in a value for the total specific surface area of 
1066.8 m2 g-1. From the XRD, porosimetry and TEM 
measurements, a pore diameter of 2.57 nm was determined. The 
N2 adsorption-desorption isotherm of S1 is typical of mesoporous 
systems with filled mesopores (see Figure S3), with the N2 
volume adsorbed and a surface area (77 m2 g-1) significantly 
decreased. 
 The dye and APTS contents on solid S1 were determined by 
elemental analysis and thermogravimetric studies, and amounted 
to 0.092 and 1.65 mmol g-1 solid, respectively. Additionally, the 
TBA content in solid S1-TBA was determined by using aptamer 
TBA-flu (5’-GGT TGG TGT GGT TGG-fluorescein-3’), which 
is similar to TBA, but is functionalised with a fluorescein dye. By 
following the decreased absorbance of TBA-flu in the solution 
after the capping process and by monitoring the TBA-flu release 
in the uncapping experiments (see SI for details), we were able to 
calculate a TBA content of 0.016 mmol g-1 solid. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Release profile of rhodamine B from solid S1-TBA in the 
absence (a) and presence (b) of α-thrombin (2.89 µM) in simulated human 
blood plasma (pH 7.25).  
 
 In order to investigate the gating properties of S1-TBA, 150 
µg of S1-TBA were suspended in 1.5 mL of simulated human 
blood plasma and the suspension was divided into two fractions. 
The first fraction was diluted with 286 µL of Milli-Q water, 
whereas the second one was treated with 286 µL of an aqueous 
solution containing 2.89 µM of α-thrombin. In both cases, 
suspensions were stirred for 90 minutes at 37°C and at certain 
times, intervals fractions were taken and centrifuged to remove 
the solid. Dye delivery at a certain time was then measured by the 
fluorescence emission of rhodamine in the solution at 572 nm 
(exc 555 nm). The delivery kinetics profile of rhodamine B in the 
presence and absence of target protein α-thrombin is displayed in 
Figure 1. In the absence of α-thrombin (curve a), solid S1-TBA 
showed a negligible dye release, indicating tight pore closure. 
The delivery of the dye was induced when α-thrombin was 
present in the solution due to the displacement of the aptamer 
from the nanoparticles as a result of aptamer-thrombin 
recognition (curve b). After 60 minutes, ca. 80% of delivery was 
reached (31% of the total adsorbed rhodamine B in solid S1-
TBA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Release of rhodamine B from S1-TBA in accordance with the 
concentration of α-thrombin added (after 60 min of reaction) in simulated 
human blood plasma (pH 7.25).  
 
Following a similar procedure, the delivery of rhodamine B 
from S1-TBA took place in accordance with the amount of α-
thrombin; the results are shown in Figure 3. As seen, the 
delivered cargo was proportional to the α-thrombin concentration, 
which is in agreement with the uncapping protocol detailed 
above. Maximum delivery was observed at an α-thrombin 
concentration of 1700 nM. Finally, a limit of detection of 2 nM 
(3) of α-thrombin was observed. One special feature of using 
gated materials for sensing applications is that it separates the 
recognition protocol (in our case, TBA-protein pair formation) 
from the signaling event, which means that sensing is 
independent of the stoichiometry of the host-guest complex, and 
sometimes, signal enhancement features are displayed. In our 
particular case, one molecule of α-thrombin was able to deliver 
ca. 115 molecules of dye at low α-thrombin concentrations (ca. 4 
nM), which is a remarkable sign of signal amplification.  
The in vitro characterisation of the nanodevice suggests that 
S1-TBA nanomaterial is sensitive to the presence of α-thrombin. 
Moreover, in order to study the possible application in the 
detection of α-thrombin in biological samples, S1-TBA was 
tested using commercially available human serum (from human 
male AB plasma). In a first step, the tolerance of the solid to 
human serum was studied by suspending 1 mg of S1-TBA in 1 
mL of serum diluted with PBS (40, 20, 10 and 5%). From these 
measurements a 10% serum dilution showed the best response 
with a limit of detection as low as 4 nM of α-thrombin (3; see 
Figure S4 and the experimental details in the SI). In a second 
step, and in order to verify the feasibility of the developed 
method, we prospectively used solid S1-TBA to determine α-
thrombin in human serum. For this purpose, and in a typical 
experiment, human serum samples were spiked with 75, 150 and 
300 nM of α-thrombin, respectively. Samples were diluted with 
PBS for a final amount of 10%, and the human α-thrombin 
contents were determined with S1-TBA material by the addition 
standard method. The obtained results are shown in Table S4. 
Remarkable recoveries in the range of 91-120% of thrombin were 
achieved. 
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Figure 3. Fluorescence of rhodamine B released from S1-TBA 
suspensions (in PBS containing 10% human serum) in the presence of α-
thrombin (56 nM), and a mixture of OVA and BSA (56 nM) after 15 
minutes of the addition. For comparative purposes, the release of 
rhodamine B from the S1-TBA suspensions in PBS containing 10% 
human serum is also shown.  
 
 In order to further investigate the selectivity of the S1-TBA 
material, control release experiments were carried out in the 
presence of other non specific binding proteins (OVA and BSA). 
In particular, the PBS containing 10% human serum was spiked 
with 56 nM of OVA and BSA and rhodamine B released after 15 
min was measured. Figure 3 shows that a mixture of OVA and 
BSA was unable to induce the uncapping of pores, which 
reinforces the selective thrombin-TBA interaction as the 
mechanism of the fluorogenic response observed. 
 In conclusion, we have prepared an aptamer-gated delivery 
system (S1-TBA) for the fluorogenic detection of thrombin. The 
sensing mechanism arises from the high affinity between an 
aptamer (TBA) and its target protein (α-thrombin). In vitro 
studies with S1-TBA showed a limit of detection of 2 nM (3) 
for α-thrombin. In addition, the hybrid nanomaterial allowed 
accurate α-thrombin detection in human serum diluted with PBS, 
also with high sensitivity (limit of detection of 4 nM (3)). The 
method, based on a simple competitive procedure, is 
undemanding and suggests that the use of aptamers can be a 
suitable approach to develop gated nanoparticles for simple 
chromo-fluorogenic assays for a wide range of bio-applications.  
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